Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Phase 1 Study of Navlimetostat Tablet Formulations

Bristol-Myers Squibb · NCT07544628

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–55 · Women only
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
64
US sites recruiting
1
Study start
April 27, 2026
Record last updated
October 7, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female

Being studied: Navlimetostat

Conditions: Healthy Participants

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Participants must be healthy adult INOCBP female with no clinically significant findings on medical history, PE, VS, 12-lead ECGs, or clinical laboratory determinations, as assessed by the investigator.
  • Participants must have BMI of 18.0 to 35.0 kg/m2.
  • Participants must have adequate laboratory test results for renal and hepatic function, as assessed by the investigator, defined as eGFR ≥ 90 mL/min/1.73m2 using the CKD-EPI equation (screening only), and total bilirubin, ALP, GGT, AST, ALT ≤ 1.5 × ULN.

Exclusion Criteria

  • Participant must not have any significant acute or chronic medical illness (in the assessment of the investigator).
  • Participant must not have current or recent GI disease: Any gastrointestinal disease within 3 months of study intervention administration that could possibly affect drug absorption, distribution, metabolism, and excretion (eg, bariatric procedure, history of pancreatitis, uncontrolled nausea or vomiting) in the opinion of the investigator.
  • Other protocol defined inclusion/exclusion criteria applies.

Recruiting US locations

  • CenExel iResearch - Decatur

    Decatur, GA 30030

    Site contact: Kimball Johnson, Site 0002 · 404-537-1281

Study contacts (from the official record)

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
  • First line of the email MUST contain NCT # and Site #.
All healthy volunteers studies in Georgia →
A Phase 1 Study of Navlimetostat Tablet Formulations (NCT07544628) | Bored Studies